Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Metastatic squamous neck cancer with occult primary
Stage/Subtype:  untreated metastatic squamous neck cancer with occult primary
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 41 for your search:
Start Over
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-412, NCI-2017-00966, 2016-003934-25, MK-3475-412, NCT03040999
Azacitidine, Durvalumab, and Tremelimumab in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-425, NCI-2017-00537, NCT03019003
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IT-01, NCI-2017-01040, NCT03058289
Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-027, NCI-2014-01952, REN13120042, UPCI #10-027, NCT01345539
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LOXO-TRK-15002, NCI-2015-01947, NCT02576431
Nivolumab with Image Guided, Stereotactic Body Radiation Therapy or Nivolumab Alone in Treating Patients with Metastatic Head and Neck Squamous Cell Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-253, NCI-2016-00261, NCT02684253
Axitinib in Treating Patients with Recurrent or Metastatic Head and Neck Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2016.040, NCI-2016-01064, NCT02762513
Afatinib Dimaleate and Cetuximab as Second-Line Treatment in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 1608018260, NCI-2017-00236, NCT02979977
Adaptive Intensity-Modulated Radiation Therapy in Treating Patients with Head and Neck Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 17-148, NCI-2017-00898, NCT03096808
Pembrolizumab in Treating Patients with Recurrent Stage III-IVB Head and Neck Squamous Cell Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: IRB15-1632, NCI-2017-00951, NCT02841748
Everolimus, Cisplatin, and Radiation Therapy in Treating Patients with Locally Advanced Head and Neck Squamous Cell Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-342, NCI-2010-00294, NCT01058408
Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9008, NCI-2012-01040, CDR0000737061, J11105, NA_00052587, NCI-2013-01545, NCT01638533
Image-Guided Cryoablation in Treating Patients with Head, Neck, and Spine Tumors
Status: Active
Phase: Phase I
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: 13-458, NCI-2014-00949, NCT02085941
Buparlisib, Cisplatin, and Radiation Therapy in Treating Patients with Stage III/IV Head and Neck Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-008, NCI-2014-02351, NCT02113878
Ficlatuzumab and Cetuximab in Treating Patients with Recurrent or Metastatic Head and Neck Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-059, NCI-2015-00056, UPCI #13-059, NCT02277197
Cetuximab, BYL719, and Intensity-Modulated Radiation Therapy in Treating Patients with Stage III-IVB Head and Neck Squamous Cell Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-116, NCI-2014-02290, NCT02282371
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B0601002, NCI-2015-00761, 2014-004107-75, NCT02315066
Ceritinib and Everolimus in Treating Patients with Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0890, NCI-2015-00062, NCT02321501
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: M14-429, NCI-2015-00519, 2014-003557-34, NCT02365662
PCA062 in pCAD-positive Tumors.
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPCA062X2101, NCI-2015-00491, 2014-003732-40, NCT02375958
A Study of Subcutaneous Recombinant Human hetIL-15 (IL15/sIL-15Ra) in Adults With Metastatic Cancers
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CNIZ985X2102J, NCI-2015-00991, AT-ONC-101, CRADA #02949, NCT02452268
WEE1 inhibitor MK-1775, Docetaxel, and Cisplatin before Surgery in Treating Patients with Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9168, NCI-2015-01064, NCT02508246
Start Over